Takedomi S[au] - Search Results

Year	Number of Results
1998	1
1999	1
2000	1
2001	2
2002	1
2007	1
2009	1
2010	1
2021	0

1

Identification of the Phr-dependent heat shock regulon in the hyperthermophilic archaeon, Thermococcus kodakaraensis.

Kanai T, Takedomi S, Fujiwara S, Atomi H, Imanaka T. Kanai T, et al. Among authors: takedomi s. J Biochem. 2010 Mar;147(3):361-70. doi: 10.1093/jb/mvp177. Epub 2009 Nov 3. J Biochem. 2010. PMID: 19887527

2

A global transcriptional regulator in Thermococcus kodakaraensis controls the expression levels of both glycolytic and gluconeogenic enzyme-encoding genes.

Kanai T, Akerboom J, Takedomi S, van de Werken HJG, Blombach F, van der Oost J, Murakami T, Atomi H, Imanaka T. Kanai T, et al. Among authors: takedomi s. J Biol Chem. 2007 Nov 16;282(46):33659-33670. doi: 10.1074/jbc.M703424200. Epub 2007 Sep 17. J Biol Chem. 2007. PMID: 17875647 Free article.

3

Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats.

Sawada Y, Takedomi S, Matsuo H, Yamano K, Iga T, Ohtani H. Sawada Y, et al. Among authors: takedomi s. Drug Metab Pharmacokinet. 2002;17(4):275-83. doi: 10.2133/dmpk.17.275. Drug Metab Pharmacokinet. 2002. PMID: 15618678 Free article.

4

Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats.

Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, Iga T. Yamano K, et al. Among authors: takedomi s. Drug Metab Dispos. 1999 Nov;27(11):1225-31. Drug Metab Dispos. 1999. PMID: 10534305

5

Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.

Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T. Yamano K, et al. Among authors: takedomi s. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):443-52. Drug Metab Dispos. 2001. PMID: 11259329

6

In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation.

Takedomi S, Matsuo H, Yamano K, Ohtani H, Sawada Y. Takedomi S, et al. J Pharm Pharmacol. 2001 May;53(5):643-51. doi: 10.1211/0022357011775974. J Pharm Pharmacol. 2001. PMID: 11370704

7

Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.

Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, Iga T. Yamano K, et al. Among authors: takedomi s. J Pharmacol Exp Ther. 2000 Mar;292(3):1118-26. J Pharmacol Exp Ther. 2000. PMID: 10688631

8

Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats.

Takedomi S, Matsuo H, Yamano K, Yamamoto K, Iga T, Sawada Y. Takedomi S, et al. Drug Metab Dispos. 1998 Apr;26(4):318-23. Drug Metab Dispos. 1998. PMID: 9531518

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results